Literature DB >> 23422741

Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database.

H Byakwaga1, K Petoumenos, J Ananworanich, F Zhang, M A Boyd, T Sirisanthana, P C K Li, C Lee, C V Mean, V Saphonn, S F S Omar, S Pujari, P Phanuphak, P L Lim, N Kumarasamy, Y M A Chen, T P Merati, S Sungkanuparph, R Ditangco, S Oka, G Tau, J Zhou, M G Law, S Emery.   

Abstract

The majority of HIV-infected patients in developing countries commences combination antiretroviral therapy (cART) with advanced disease. We examined predictors of disease progression in patients initiating cART with CD4 count ≤200 cells/mm(3) in the TREAT Asia HIV Observational Database. The main outcome measure was progression to either an AIDS-defining illness or death occurring 6 months after initiation of cART. We used survival analysis methods. A total of 1255 patients contributed 2696 person years of follow-up; 73 were diagnosed with AIDS and 9 died. The rate of progression to the combined end point was 3.0 per 100 person years. The factors significantly associated with a higher risk of disease progression were Indian ethnicity, infection through intravenous drug use, lower CD4 count, and hemoglobin ≤130 g/dL at 6 months. In conclusion, measurements of CD4 count and hemoglobin at month 6 may be useful for early identification of disease progression in resource-limited settings.

Entities:  

Keywords:  HIV; antiretroviral therapy; disease progression; resource-limited settings

Mesh:

Substances:

Year:  2013        PMID: 23422741      PMCID: PMC3716846          DOI: 10.1177/1545109712469684

Source DB:  PubMed          Journal:  J Int Assoc Provid AIDS Care        ISSN: 2325-9574


  42 in total

1.  The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy.

Authors:  Colette J Smith; Caroline A Sabin; Fiona C Lampe; Sabine Kinloch-de-Loes; Helen Gumley; Anne Carroll; Beth Prinz; Mike Youle; Margaret A Johnson; Andrew N Phillips
Journal:  AIDS       Date:  2003-05-02       Impact factor: 4.177

2.  Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Authors:  F Bonnet; R Thiébaut; G Chêne; D Neau; J-L Pellegrin; P Mercié; J Beylot; F Dabis; R Salamon; P Morlat
Journal:  HIV Med       Date:  2005-05       Impact factor: 3.180

3.  A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.

Authors:  Jens D Lundgren; Amanda Mocroft; Jose M Gatell; Bruno Ledergerber; Antonella D'Arminio Monforte; Philippe Hermans; Frank-Detlef Goebel; Anders Blaxhult; Ole Kirk; Andrew N Phillips
Journal:  J Infect Dis       Date:  2002-01-03       Impact factor: 5.226

4.  Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program.

Authors:  P A Selwyn; D Hartel; W Wasserman; E Drucker
Journal:  Am J Public Health       Date:  1989-10       Impact factor: 9.308

5.  Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France.

Authors:  Olivier Lortholary; Arnaud Fontanet; Nathalie Mémain; Antoine Martin; Karine Sitbon; Françoise Dromer
Journal:  AIDS       Date:  2005-07-01       Impact factor: 4.177

6.  Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

Authors:  B Ledergerber; A Mocroft; P Reiss; H Furrer; O Kirk; M Bickel; C Uberti-Foppa; C Pradier; A D'Arminio Monforte; M M Schneider; J D Lundgren
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

7.  Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.

Authors:  Yared Mekonnen; Nicole H Dukers; Eduard Sanders; Wendelien Dorigo; Dawit Wolday; Ab Schaap; Ronald B Geskus; Roel A Coutinho; Arnaud Fontanet
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

8.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Authors:  B Ledergerber; M Egger; V Erard; R Weber; B Hirschel; H Furrer; M Battegay; P Vernazza; E Bernasconi; M Opravil; D Kaufmann; P Sudre; P Francioli; A Telenti
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

10.  Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database.

Authors:  Preeyaporn Srasuebkul; Poh Lian Lim; Man Po Lee; Nagalingeswaran Kumarasamy; Jialun Zhou; Thira Sirisanthana; Patrick C K Li; Adeeba Kamarulzaman; Shinichi Oka; Praphan Phanuphak; Saphonn Vonthanak; Tuti P Merati; Yi-Ming A Chen; Somnuek Sungkanuparph; Goa Tau; Fujie Zhang; Christopher K C Lee; Rossana Ditangco; Sanjay Pujari; Jun Y Choi; Jeffery Smith; Matthew G Law
Journal:  Clin Infect Dis       Date:  2009-04-01       Impact factor: 9.079

View more
  1 in total

Review 1.  Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review.

Authors:  Jessica L Castilho; Vlada V Melekhin; Timothy R Sterling
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.